The scope of this project includes personnel necessary to effectively fulfill OSE's goals and objectives for the various program offices within OSE. These offices include the immediate office (IO),…
Ended Awarded Last action
- Contract number
- 75F40120F19102
- Awardee
-
Brillient Corporation UEI MMAVC7UGLJ78
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $5,628,718
Award facts
- Contract value 83% obligated
-
- $5,628,718.34 Current, with exercised options
- $6,786,823.90 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$490,569 | |
| Supplemental Agreement for work within scope | $278,052 | |
| Other Administrative Action | $0 | |
| Original award | $5,841,235 |
About this award
This federal contract was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to Brillient Corporation, a management, technology, and business process management firm. The $6,786,823.90 contract provides personnel to effectively fulfill the goals and objectives of the FDA's Office of Surveillance and Epidemiology (OSE), which includes the Immediate Office (IO), Office of Pharmacoepidemiology (OPE), and other program offices. The contract was awarded on December 18, 2019 and has a completion date of September 1, 2021. It was issued as a Blanket Purchase Agreement (BPA) call under the Professional Services Schedule (PSS) of the General Services Administration (GSA). No set-aside designation was used.
Description
The scope of this project includes personnel necessary to effectively fulfill OSE's goals and objectives for the various program offices within OSE. These offices include the immediate office (IO), office of pharmacoepidemiology (OPE) and the o
Quick answers
Who was awarded contract 75F40120F19102?
75F40120F19102 was awarded to Brillient Corporation by Food and Drug Administration (Department of Health and Human Services) on December 18, 2019.
How much is contract 75F40120F19102 worth?
The government has obligated $5,628,718 on 75F40120F19102. Its potential value, with all options, is $6,786,824.
Is contract 75F40120F19102 an order under another contract?
Yes. 75F40120F19102 is a BPA call under GS00F012BA-HHSF223201810005B, a blanket purchase agreement, on The Professional Services Schedule (PSS).
Was contract 75F40120F19102 competed?
The extent of competition for 75F40120F19102 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award